(Source: Transgene SA) 50f21935-50e1-40d7-b527-17e2187026e1.pdf Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection Strasbourg, France, November 4, 2015 - Transgene SA (Euronext: TNG) today announced that the first patient has been dosed in a clinical trial with its immunotherapy product candidate TG1050 for the treatment of chronic hepatitis B virus (HBV) infection. This first-in-humans trial is an international, randomized, multi-center, double-blind, placebo-controlled safety and dose-finding study evaluating TG1050 in patients who are currently being treated for chronic HBV infection with standard-of-care antiviral therapy. The primary...
↧